Lupin’s stock gained over 3% in early trade on Wednesday after the company announced plans to build a new state-of-the-art pharmaceutical manufacturing facility in Coral Springs, Florida. The move marks a major expansion of the Indian drugmaker’s footprint in the US and reinforces its position as a leading player in the global respiratory segment.
A
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.